Dickinson Rebecca, Hamrosi Kim, Knapp Peter, Aslani Parisa, Sowter Julie, Krass Ines, Raynor David K
School of Healthcare, University of Leeds, Leeds, UK.
Int J Pharm Pract. 2013 Aug;21(4):207-15. doi: 10.1111/j.2042-7174.2012.00252.x. Epub 2012 Nov 13.
To explore participants' opinions and preferences on tailored written medicines information.
Forty-five participants were recruited to eight focus groups, run concurrently in Australia (23 participants in four groups) and the UK (22 participants in four groups). Participants were provided with exemplar leaflets for a cardiovascular medicine based on the angiotensin-converting enzyme (ACE) inhibitor ramipril, which was tailored for a man aged 55 with hypertension. Reference to other indications of the medicine, children's doses, pregnancy and breast-feeding information were removed. A topic guide directed the discussion and explored preferences and opinions on tailored leaflets. Focus group discussions were recorded, transcribed verbatim and content analysed using adapted cross-case study analysis.
Participants welcomed the concept of tailored information, desiring shorter and more relevant information. Information tailored to their condition or disease was most sought-after, followed by tailoring by age or gender. However, some participants voiced concerns about the potential for the wrong information being given to patients who would be unable to recognise that it was incorrect. Other concerns included how tailoring might impact upon the quality of information available and the feasibility of delivery, especially regarding the legal implications (Australia) and the cost (UK). A key finding was the participants' desire for a truly individualised approach to tailoring medicines information, as opposed to the generalised tailored information provided in the study. Participants said they would value having spoken communication with a healthcare professional at the same time as they received tailored leaflets.
Most participants welcomed tailored leaflets but overall valued a more personalised approach than the generalised tailored information we provided. Despite concerns about quality and delivery, many felt tailoring written medicines information could improve the relevance of the information to the individual and potentially encourage them to value it.
探讨参与者对定制书面药品信息的看法和偏好。
招募了45名参与者，分成8个焦点小组，同时在澳大利亚（4个小组共23名参与者）和英国（4个小组共22名参与者）开展。为参与者提供了一份基于血管紧张素转换酶（ACE）抑制剂雷米普利的心血管药物示例传单，该传单是为一名55岁患有高血压的男性量身定制的。去除了关于该药物其他适应症、儿童剂量、妊娠和母乳喂养信息的内容。一份主题指南指导讨论，并探讨对定制传单的偏好和看法。焦点小组讨论进行了录音，逐字转录，并采用适应性跨案例研究分析进行内容分析。
参与者欢迎定制信息的概念，希望获得更简短、更相关的信息。最受欢迎的是根据其病情或疾病定制的信息，其次是按年龄或性别定制。然而，一些参与者对可能向无法识别错误信息的患者提供错误信息表示担忧。其他担忧包括定制可能如何影响可用信息的质量和传递的可行性，特别是在法律影响（澳大利亚）和成本（英国）方面。一个关键发现是，参与者希望采用真正个性化的方法来定制药品信息，而不是研究中提供的一般化定制信息。参与者表示，他们重视在收到定制传单的同时与医疗保健专业人员进行口头沟通。
大多数参与者欢迎定制传单，但总体上更看重比我们提供的一般化定制信息更个性化的方法。尽管对质量和传递存在担忧，但许多人认为定制书面药品信息可以提高信息与个人的相关性，并可能促使他们重视这些信息。
